Skip to main content

Coherus Oncology, Inc.

CHRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001512762

No open-market purchases or sales by Coherus Oncology, Inc. insiders were filed in the last 90 days; 146 institutions reported holding it in 13F filings for Q2 2026, worth $98.5M in total; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Coherus Oncology, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of CHRS: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders163161−2
Shares78.4M86.8M+8.37M (+10.7%)
Value$536.5M$371.1M−$165.4M (−30.8%)

New holders (27)

Institutions that held Coherus Oncology, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to CHRS in Q2 2023
InstitutionSharesValue% of portfolio
Point72 Asset Management, L.P.960,021$4.10M0.01%
Woodline Partners LP500,000$2.13M0.03%
Knott David M Jr245,010$1.05M0.44%
HRT Financial LP233,791$998.0K0.01%
Allianz Asset Management GmbH216,600$924.9K0.00%
Ghisallo Capital Management LLC150,000$640.5K0.08%
AXA S.A.142,400$608.0K0.00%
Graham Capital Management, L.P.128,539$548.9K0.02%
Courage Capital Management LLC50,000$214.0K0.59%
Virtu Financial LLC39,021$167.0K0.01%
Levin Capital Strategies, L.P.30,000$128.1K0.01%
Y-Intercept (Hong Kong) Ltd27,023$115.4K0.01%
Baird Financial Group, Inc.25,435$108.6K0.00%
Wolverine Trading, LLC25,829$108.2K0.00%
Captrust Financial Advisors23,745$101.4K0.00%
Walleye Capital LLC20,654$88.2K0.00%
Sargent Investment Group, LLC19,692$84.1K0.02%
Ergoteles LLC16,600$70.9K0.00%
Boothbay Fund Management, LLC15,000$64.0K0.00%
Eagle Asset Management Inc13,129$56.1K0.00%
Centiva Capital, LP11,300$48.3K0.00%
Metropolitan Life Insurance Co4,053$17.3K0.00%
Cutler Group LP2,000$8.00K0.00%
Lindbrook Capital, LLC375$1.60K0.00%
Newbridge Financial Services Group, Inc.300$1.28K0.00%
Allworth Financial LP100$4270.00%
Harbour Investments, Inc.90$3840.00%

Sold out (29)

Institutions that held Coherus Oncology, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.